Amedisys (NASDAQ:AMED) Posts Earnings Results, Beats Expectations By $0.01 EPS

Amedisys (NASDAQ:AMED) issued its earnings results on Wednesday. The health services provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01, Briefing.com reports. The firm had revenue of $571.41 million during the quarter, compared to analyst estimates of $565.38 million. Amedisys had a negative net margin of 0.44% and a positive return on equity of 12.76%. The business’s revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.00 earnings per share.

Amedisys Stock Up 0.1 %

Amedisys stock traded up $0.08 during trading hours on Thursday, reaching $91.13. The stock had a trading volume of 62,433 shares, compared to its average volume of 275,624. The company has a market cap of $2.98 billion, a price-to-earnings ratio of -292.96, a PEG ratio of 4.29 and a beta of 0.86. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.05 and a quick ratio of 1.05. The business’s 50 day moving average price is $92.63 and its 200-day moving average price is $93.37. Amedisys has a 52 week low of $73.10 and a 52 week high of $96.44.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on AMED shares. Raymond James reissued a “market perform” rating on shares of Amedisys in a research note on Tuesday, March 26th. Royal Bank of Canada boosted their target price on shares of Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 25th. Cantor Fitzgerald reissued a “neutral” rating and set a $101.00 target price on shares of Amedisys in a research note on Thursday. Finally, StockNews.com started coverage on shares of Amedisys in a research note on Monday, April 8th. They issued a “buy” rating for the company. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $97.50.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.